Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 5 Breast Neoplasms 5 Neoplasms 3 Ovarian Neoplasms 2 Neoplasm Metastasis 2 mCRPC 1 Wilms Tumor 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myeloid, Acute 1 Hepatoblastoma 1 Hemangiosarcoma 1 Extensive Stage Lung Small Cell Carcinoma 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Adenocarcinoma 1

Interventions

Oxaliplatin 9 Capecitabine 9 Fluorouracil 7 pembrolizumab 6 Paclitaxel 6 Leucovorin 6 Cisplatin 5 zolbetuximab 4 trastuzumab deruxtecan 3 enzalutamide 3 durvalumab 3 cemiplimab 3 Trastuzumab 3 Gemcitabine 3 Docetaxel 3 fludarabine 2 darolutamide 2 Taxes 2 Ramucirumab 2 Radiotherapy, Image-Guided 2 Radiosurgery 2 Pemetrexed 2 Nivolumab 2 Irinotecan 2 Cyclophosphamide 2 Carboplatin 2 Albumin-Bound Paclitaxel 2 130-nm albumin-bound paclitaxel 2 vistusertib 1 tucatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × talazoparib × 90 days × Clear all

NCT06844383 2026-04-24

TALENT

Prostate Cancer Clinical Trials Consortium

Phase 2 Recruiting

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡